Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction to: Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO) ; volume:14 ; number:6 ; day:30 ; month:5 ; year:2024 ; pages:1495-1496 ; date:6.2024
Dermatology and therapy ; 14, Heft 6 (30.5.2024), 1495-1496, 6.2024
- Urheber
-
Pinter, Andreas
Costanzo, A.
Khattri, S.
Smith, S. D.
Carrascosa, J. M.
Tada, Y.
Riedl, E.
Reich, A.
Brnabic, A.
Haustrup, N.
Lampropoulou, A.
Lipkovich, I.
Kadziola, Z.
Paul, Carle F.
Schuster, C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-024-01105-3
- URN
-
urn:nbn:de:101:1-2408182126380.749461089800
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pinter, Andreas
- Costanzo, A.
- Khattri, S.
- Smith, S. D.
- Carrascosa, J. M.
- Tada, Y.
- Riedl, E.
- Reich, A.
- Brnabic, A.
- Haustrup, N.
- Lampropoulou, A.
- Lipkovich, I.
- Kadziola, Z.
- Paul, Carle F.
- Schuster, C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
ActiPso: Definition von Aktivitätstypen der Psoriasis
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Evidenz-basierte Therapie der Psoriasis : Schwerpunkt Biologics
Evidenz-basierte Therapie der Psoriasis : Schwerpunkt Biologics
Autoimmunphänomene in der Therapie der Psoriasis mit Biologics
Evidence-based therapy of Psoriasis: focus on biologics
Biologics als neue Therapieoptionen in der Behandlung der Psoriasis und Psoriasis-Arthritis
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
ActiPso: Definition von Aktivitätstypen der Psoriasis
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Evidenz-basierte Therapie der Psoriasis : Schwerpunkt Biologics
Evidenz-basierte Therapie der Psoriasis : Schwerpunkt Biologics
Autoimmunphänomene in der Therapie der Psoriasis mit Biologics
Evidence-based therapy of Psoriasis: focus on biologics
Biologics als neue Therapieoptionen in der Behandlung der Psoriasis und Psoriasis-Arthritis
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)
Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO)
ActiPso: Definition von Aktivitätstypen der Psoriasis
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
Evidenz-basierte Therapie der Psoriasis : Schwerpunkt Biologics
Evidenz-basierte Therapie der Psoriasis : Schwerpunkt Biologics
Autoimmunphänomene in der Therapie der Psoriasis mit Biologics
Evidence-based therapy of Psoriasis: focus on biologics